Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) FCF Margin (2018 - 2025)

Arcturus Therapeutics Holdings' FCF Margin history spans 8 years, with the latest figure at 224.28% for Q4 2025.

  • For Q4 2025, FCF Margin fell 22303.0% year-over-year to 224.28%; the TTM value through Dec 2025 reached 90.82%, down 5117.0%, while the annual FY2025 figure was 90.82%, 5117.0% down from the prior year.
  • FCF Margin reached 224.28% in Q4 2025 per ARCT's latest filing, down from 101.06% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 474.08% in Q2 2023 to a low of 2030.47% in Q1 2021.
  • Average FCF Margin over 5 years is 336.55%, with a median of 85.73% recorded in 2023.
  • Peak YoY movement for FCF Margin: crashed -157695bps in 2021, then surged 150497bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 694.89% in 2021, then soared by 115bps to 102.07% in 2022, then plummeted by -110bps to 10.09% in 2023, then surged by 88bps to 1.25% in 2024, then plummeted by -17879bps to 224.28% in 2025.
  • Per Business Quant, the three most recent readings for ARCT's FCF Margin are 224.28% (Q4 2025), 101.06% (Q3 2025), and 20.33% (Q2 2025).